Why the study?
Evaluating the safety of ceasing cardioprotective pharmacotherapy in recovered chemotherapy-induced cardiotoxicity represents an evidence-free zone in clinical practice.
Does the cessation of cardioprotective pharmacotherapy affect safety in patients with recovered chemotherapy-induced cardiotoxicity?
Does the cessation of cardioprotective pharmacotherapy affect safety in patients with recovered chemotherapy-induced cardiotoxicity?
The COP-RCT pilot study is designed to provide initial evidence on the safety of withdrawing cardioprotective therapy in patients who have recovered from chemotherapy-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Caution against withdrawing cardioprotective therapy; pilot RCT leaves open definitive safety assessment in recovered cardiotoxicity.
Cessation Of Pharmacotherapy In Recovered Chemotherapy-induced cardioToxicity (COP-RCT) is one of the first studies currently underway to evaluate the safety of ceasing CPT in recovered CTRCD. The results will inform clinical practice in this evidence-free zone.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: